Lymphocytic Neoplasm

Whole exome sequencing of 6 chronic lymphocytic leukemia patients with acquired resistance to ibrutinib determined 5/6 patients harbored a C481S mutation in BTK.

PMID 24869598 · Woyach et al., 2014 · Open in CIViC

In a trial of 308 patients with chronic lymphocytic leukemia treated with ibrutinib, 31 discontinued treatment due to disease progression (13 CLL progression, 18 Richter’s transformation). 11/13 patie… (full text at CIViC)

PMID 26182309 · Maddocks et al., 2015 · Open in CIViC

The effective cohort in this study was 11 CLL patients who were first treated with ibrutinib and then on progression treated with venetoclax until progression. Patient samples were sequenced before an… (full text at CIViC)

PMID 32232486 · Lucas et al., 2020 · Open in CIViC

A preclinical study investigated BTK inhibitor ibrutinib as a potential inhibitor for patients with pre-BCR + B cell acute lymphoblastic leukemia (B-ALL). In validating the significance of BTK and BLK… (full text at CIViC)

PMID 28031181 · Kim et al., 2017 · Open in CIViC

A patient cohort of 308 individuals was created from trials of Ibrutinib in CLL (see Maddocks 2015, PMID: 26182309). A secondary cohort was created from a prospective collection of 112 patients. 83/… (full text at CIViC)

PMID 28418267 · Woyach et al., 2017 · Open in CIViC

This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Only genes that have been confirmed by other similar studies were added to … (full text at CIViC)

PMID 28985567 · Reddy et al., 2017 · Open in CIViC

Case report of a patient with CLL and Richter-transformed relapse under ibrutinib (after an initial partial response for 10 months). Sequencing of sequential samples of this patient revealed a novel B… (full text at CIViC)

PMID 27626698 · Sharma et al., 2016 · Open in CIViC

The signalling adaptor CARD11 is required for constitutive NF-kappaB pathway activity and survival in ABC DLBCL. Roughly 10% of ABC DLBCLs have mutant CARD11 isoforms that activate NF-kappaB, but the … (full text at CIViC)

PMID 20054396 · Davis et al., 2010 · Open in CIViC

This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC)

PMID 21796119 · Morin et al., 2011 · Open in CIViC

Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma.

PMID 17891190 · Jares et al., 2007 · Open in CIViC

Bone marrow specimens from 20/47 patients treated with bortezomib were analyzed. Researchers analyzed CCND1, CCND2, and CCND3 expression using real-time PCR. Results show all patients with CCND1 ove… (full text at CIViC)

PMID 20578819 · Ngo et al., 2010 · Open in CIViC

A pharmacodynamic study (NCT00420056) of 17 mantle cell lymphoma MCL patients was performed using the CDK4/6 inhibitor palbociclib (PD0332991). Patients were verified by IHC, FISH or molecular testing…

Treatment of Notch-driven T-cell leukemia in Ccnd3 knockout mice with Palbociclib (PD-0332991) significantly increased median survival.

PMID 23079656 · Sawai et al., 2012 · Open in CIViC

This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC)

PMID 21796119 · Morin et al., 2011 · Open in CIViC

Many mutations in CCND3 have been described in the cited study and other studies of BL

PMID 30617194 · Grande et al., 2019 · Open in CIViC

In an in vitro study, cells transduced with CD19 delta5-6 and CD19 delta2 show significantly no response to CART-19 therapy compared to CD19-FL transduced cells.

PMID 26516065 · Sotillo et al., 2015 · Open in CIViC

This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC)

PMID 21796119 · Morin et al., 2011 · Open in CIViC

This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC)

PMID 21796119 · Morin et al., 2011 · Open in CIViC

A somatic out-of-frame CD74intr::PDGFRB rearrangement joined CD74 exon 1 to PDGFRB exon 11 and retained 75 bp of CD74 intronic sequence containing a premature stop codon. Rather than producing a conve… (full text at CIViC)

PMID 36810896 · Sadras et al., 2023 · Open in CIViC

A 22-month-old patient with high-risk Philadelphia chromosome-like B-cell acute lymphoblastic leukemia harboring CD74intr::PDGFRB had 46.3% residual bone marrow blasts at the end of induction therapy.… (full text at CIViC)

PMID 36810896 · Sadras et al., 2023 · Open in CIViC

MCD subtype is based on the co-occurrence of MYD88.L265P and CD79B mutations.

PMID 29641966 · Schmitz et al., 2018 · Open in CIViC

This is one of the genetic features of this subgroup

PMID 32289277 · Wright et al., 2020 · Open in CIViC

In a preclinical study using 5 CD80-overexpressing Burkitt B-cell lymphoma cell lines (Raji, Daudi, Ramos, DHL4, 2F7), treatment with the anti-CD80 monoclonal antibody galiximab (25–100 µg/mL) inhibit… (full text at CIViC)

PMID 22267549 · Martinez-Paniagua et al., 2012 · Open in CIViC

This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Some concerns about the validity of the results have been expressed in subs… (full text at CIViC)

PMID 28985567 · Reddy et al., 2017 · Open in CIViC

This study shows that patients with TMEM30A mutations respond better to standard of care (R-CHOP). The functional data implies these mutations may also sensitize more generally to other chemotherapies… (full text at CIViC)

PMID 32094924 · Ennishi et al., 2020 · Open in CIViC

This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC)

PMID 21796119 · Morin et al., 2011 · Open in CIViC

CDKN2A/B deletions were poor prognostic factors for both overall survival (OS) (HR = 2.15, 95% CI 1.82-2.54) and event-free survival (EFS)/disease-free survival (DFS)/relapse-free survival (RFS) (HR =… (full text at CIViC)

PMID 30592434 · Zhang et al., 2019 · Open in CIViC

A total of thirteen studies including 2857 patients were combined in a meta-analysis. Combined HRs suggested that CDKN2A/B deletions were poor prognostic factors for both overall survival (OS) (HR = 2… (full text at CIViC)

PMID 30592434 · Zhang et al., 2019 · Open in CIViC

Mutations have been described in several studies including the one cited.

PMID 30617194 · Grande et al., 2019 · Open in CIViC

This study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a BCR-ABL1-like (Ph-like) gene expression signature. RT-PCR or RNAseq perf… (full text at CIViC)

PMID 28408464 · Reshmi et al., 2017 · Open in CIViC

Mutations in this gene have been described as a feature of some BLs as per this study

PMID 30617194 · Grande et al., 2019 · Open in CIViC

This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC)

PMID 21796119 · Morin et al., 2011 · Open in CIViC

In a retrospective study of 5,290 chronic lymphocytic leukemia (CLL) patients where chromosome-banding analysis (CBA) data was available, karyotype complexity was assessed for clinical impact. Karyoty… (full text at CIViC)

PMID 30602617 · Baliakas et al., 2019 · Open in CIViC

CLTC-ALK is one of the most common ALK fusions found in diffuse large B cell lymphoma (DLBCL). In a retrospective study of 38 patients with ALK-rearranged DLBCL, 3 were CD20 positive. Only one showed … (full text at CIViC)

PMID 19636007 · Laurent et al., 2009 · Open in CIViC

A cell line called LM1 was established from the bone marrow of a 13 year old female patient with relapsed CLTC-ALK positive diffuse large B-cell lymphoma (DLBCL). The patient had been heavily treated … (full text at CIViC)

PMID 21494621 · Cerchietti et al., 2011 · Open in CIViC

In a 56-year-old female diagnosed with B-lymphoblastic leukemia/lymphoma (B-ALL), transcriptome sequencing (RNA-seq) identified a CNTRL::ABL1 fusion. At diagnosis, the patient had a white blood cell c… (full text at CIViC)

PMID 37103615 · Tan et al., 2023 · Open in CIViC

In a 15-year-old male with B-lymphoblastic leukemia/lymphoma (B-ALL), a novel CNTRL::ABL1 was identified during screening of 212 childhood B-cell acute lymphoblastic leukemia cases. Samples lacking kn… (full text at CIViC)

PMID 33707599 · Hsu et al., 2021 · Open in CIViC

A 37 year old, heavily pretreated (including thalidomide and lenalidomide) patient with IgG-kappa multiple myeloma was sequenced following extramedullary relapse. A high number of alterations were obs… (full text at CIViC)

PMID 23480694 · Egan et al., 2013 · Open in CIViC

Two phase II clinical trials examined mTOR inhibitors, everolimus (NCT00436618) or temsirolimus (NCT00290472) in relapsed/refractory FL. Tumour blocks were collected from these trials for 21 cases (15… (full text at CIViC)

PMID 39188028 · Kumar et al., 2024 · Open in CIViC

This study showed that CREBBP and EP300 were recurrently mutated in DLBCL

PMID 21390126 · Pasqualucci et al., 2011 · Open in CIViC

Mullighan et al analyzed a cohort of 71 diagnosis-relapse cases and 270 acute leukaemia cases that did not relapse. The authors found that 18.3% of relapse cases had sequence or deletion mutations of … (full text at CIViC)

PMID 21390130 · Mullighan et al., 2011 · Open in CIViC

Lymphoma cell lines with CREBBP R1446C mutations demonstrated heightened sensitivity to the HDAC3 inhibitor BRD3308. Both CREBBP R1446C and CREBBP KO cell lines showed significantly greater inhibition… (full text at CIViC)

PMID 31915197 · Mondello et al., 2020 · Open in CIViC

In vitro expression experiments of CRLF2 F232C in murine BaF3 cells and human UT7 cells show that this mutation leads to constitutive dimerization and cytokine-independent signaling. This leads to tra… (full text at CIViC)

PMID 20018760 · Yoda et al., 2010 · Open in CIViC

The CRLF2 Phe232Cys somatic mutation was identified in 3/14 adult B-ALL specimens overexpressing CRLF2. Functional studies in BaF3 cells demonstrated constitutive dimerization, and retains ability to … (full text at CIViC)

PMID 20018760 · Yoda et al., 2010 · Open in CIViC

CRLF2 is overexpressed in 7% of B cell ALL. In KZF1-mutated, BCR-ABL1-negative ALL, also refers as “Ph-like ALL” , 50 % of these “Ph-like ALL” carry rearrangements of CRLF2 (CRLF2r). In particular, IG… (full text at CIViC)

PMID 22897847 · Roberts et al., 2012 · Open in CIViC

To investigate the therapeutic potential of JAK inhibitors in pediatric B-ALL, the authors examined the efficacy of rapamycin in murine xenograft models of 8 pediatric B-ALL cases. Five xenografts (I … (full text at CIViC)

PMID 22955920 · Maude et al., 2012 · Open in CIViC

Lack of association of CRLF2 V2del with any clinical value in acute lymphocytic leukemia.

PMID 29449437 · Sinclair et al., 2018 · Open in CIViC